Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7308118 | 0.86 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1BTN3A1CYP3A4 | |
| SCHEMBL30823329 | 0.79 | HCAR2 (0.48) | ALDH1A1MAPK1L3MBTL1BTN3A1CYP3A4 | |
| SCHEMBL6085993 | 0.78 | PTGS1 (0.35) | MAPK1 | |
| SCHEMBL25182464 | 0.78 | LTA4H (0.47) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL7715985 | 0.75 | L3MBTL1 (0.36) | MAPK1L3MBTL1BTN3A1 | |
| SCHEMBL7715986 | 0.75 | L3MBTL1 (0.36) | MAPK1L3MBTL1BTN3A1 | |
| SCHEMBL16757577 | 0.75 | LTA4H (0.44) | ALDH1A1MAPK1L3MBTL1BTN3A1TDP1 | |
| SCHEMBL329059 | 0.74 | BTN3A1 (0.41) | ALDH1A1MAPK1L3MBTL1FAAHBTN3A1 | |
| SCHEMBL329058 | 0.74 | BTN3A1 (0.41) | ALDH1A1MAPK1L3MBTL1FAAHBTN3A1 | |
| SCHEMBL31480636 | 0.74 | LTA4H (0.46) | ALDH1A1MAPK1L3MBTL1BTN3A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123197-A1 | METHOD OF MAKING A CROSS METATHESIS PRODUCT | NATIONAL SCIENCE FOUNDATION | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123197-A1 | METHOD OF MAKING A CROSS METATHESIS PRODUCT | DUOX2, DUOX1, RNF168 | ALDH1A1 1487/4885MAPK1 3660/4885L3MBTL1 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.